The discrepancies between the results of UCHL1 levels in MS patients and the control group between the present study and the above research may be due to the assessment of the quantity of the enzyme in different body fluids, diverse research methodologies, and different characteristics of the cohorts. This evidence concerns the gene UCHL1 and myeloid sarcoma.